Name: Equity Multiplier

Definition: The equity multiplier shows how much total assets the company controls for every dollar invested by shareholders. It reflects how much debt is being used to stretch owners’ equity. A higher multiplier means greater use of debt to amplify returns — but also amplifies risk if things go wrong. Lower multipliers suggest a safer, more self-funded business.

Interpretation:
• In '2021', GNTA's equity multiplier was 1.03, representing the level of financial leverage utilized. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2021' stood at 1.16.
• In '2022', GNTA's equity multiplier was 1.07, representing the level of financial leverage utilized. The increase compared to '2021' may signal growing financial pressure. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2022' stood at 0.96. Industry average declined by 0.20 from previous year.
• In '2023', GNTA's equity multiplier was 1.09, representing the level of financial leverage utilized. The increase compared to '2022' may signal growing financial pressure. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2023' stood at 1.29. Industry average increased by 0.33 compared to previous year.
• In '2024', GNTA's equity multiplier was 1.19, representing the level of financial leverage utilized. The increase compared to '2023' may signal growing financial pressure. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2024' stood at 1.14. Industry average declined by 0.15 from previous year.
Overall, GNTA's equity multiplier has steadily improved over the past 4 years.

Formula: Equity Multiplier = Total Assets / Shareholders' Equity

Good Range: Usually ranges from 1.5 to 3 depending on industry.